SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it intends to offer $175.0 million aggregate principal amount of its Convertible Senior Notes due 2027 (the “Notes”) in a private offering (the “offering”) to qualified institutional

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 30, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2020 financial results after the close of market on Thursday, May 7, 2020 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time to

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 9, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 19 th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 6:20 am PT / 9:20 am ET . Tricida will provide a company overview, business

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 24, 2020-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

Take the Kidney Risk Quiz at MinuteForYourKidney.Org SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 24, 2020-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Cowen 40 th Annual Health Care Conference on Monday, March 2, 2020 at 11:10 am PT / 2:10 pm ET . Geoff Parker , Tricida’s Chief Financial Officer, will provide a